Contact Us
Group

Innovative genetic medicines for metabolic and autoimmune diseases. Powered by RNAi.

SanegeneBio is developing a globally integrated drug discovery and development engine, achieving best-in-class potential with LEAD™ technology.

About Us
Two scientists in lab coats, safety goggles, and masks look through a glass panel while holding up a conical flask.

Pioneering transformative therapies for metabolic and autoimmune diseases

We’re advancing a pipeline of best-in-class therapeutics targeting obesity and metabolic disorders, complement-mediated immune diseases, and cardiovascular diseases.

Our Pipeline
a abstract image of clear, glowing spheres or bubbles floating in a blue, futuristic liquid.
A male researcher wearing a white lab coat and safety goggles, uses a micropipette to work on a sample.
A wall of multiple digital screens shows a detailed and glowing representation of a DNA helix and genetic data.

Ligand and Enhancer Assisted Delivery (LEAD™) Technology

Our LEAD™ platform utilizes novel receptor-mediated internalization mechanisms and tailored enhancers to achieve targeted delivery to extrahepatic tissues and cells of therapeutic relevance.

Our Technology

What Makes Us Different

  • Targeted to adipocytes, skeletal myocytes, and other therapeutically relevant cell types
  • Receptor-mediated delivery with defined mechanisms and tunable pharmaceutical properties
  • Bi-annual subcutaneous dosing potential with excellent GaINAc-like safety profile

SanegeneBio pioneers RNAi medicines with optimized payloads and proprietary delivery technologies for both liver and extra-hepatic targets to expand therapeutic potential.

Clinical stage, fully integrated and global biotechnology company, laser focused on unlocking the full potential of RNAi medicines

Therapeutic area focus on metabolic/obesity and complement mediated diseases, leveraging both well-understood and novel gene targets

Delivery technologies, enabling safe, selective and durable mRNA silencing in tissues of therapeutic relevance

>$150MM raised to date to support growing pipeline

Contact Us